Table 2. Summary of AEs that occurred in the treatment of 6 malignant and 2 benign diseases with USgFU.

Disease	Case	Adverse event	Incidence
Malignant
Liver	2201	Skin burn 493	35.30% (777/2201)
		Rib injury 7
		Chest wall injury 2
		Vertebra injury 4
		Severe abdomen pain 39
		ALT/AST elevation 81
		Jaundice aggravation 2
		Cholecystitis 5
		Intrahepatic cholangiectasis 5
		Gastroenteric dysfunction 22
		Rupture of esophageal varices 1
		Supraventricular tachycardia/palpitation 12
		Hydropericardium 2
		Hypertension 8
		Bleeding/liquefaction 7
		Tumor rupture 2
		Intrahepatic metastasis 7
		Lung embolism 2
		Hydrothorax 57
		Pneumonedema 1
		Asthma 2
		Hematuria 8
		Creatine elevation 2
		Renal failure 1
		High fever 4
		Death 1
Pancreas	1717	Burn 51	8.74% (150/1717)
		Vertebra burn 2
		Diabetes 22
		Jaundice aggravation 10
		Pancreatitis 32
		Steatorrhea 13
		Gastroenteric dysfunction 13
		Bleeding 2
		Occlusion of the superior mesenteric artery 1
		Collapse 3
		Hepatic abscess 1
Bone	224	Skin burn 10	20.54% (46/224)
		Nerve injury 14
		Infection 2
		Fracture 10
		Epiphyseal separation 1
		ALP elevation 5
		Hemoglobinuria 1
		Tumor rupture 2
		Death 1
Breast	167	Skin burn 19	11.38% (19/167)
Soft tissues	81	Skin burn 5	14.81% (12/81)
		Cutaneous necrosis 4
		Nerve injury 3
Prostate	375	Skin burn 27	28.53% (107/375)
		Hematuria 65
		Urinary obstruction 9
		Urethral stricture 4
		Incontinence 2
Benign
Uterine fibroid	5526	Skin burn 112	10.19% (563/5526)
		Vertebra burn 23
		Nerve injury 169
		Severe/prolonged abdomen pain 92
		Hematuria 159
		Urinary irritation 1
		Hemafecia 1
		Gastroenteric dysfunction 6
Prostate hyperplasia	883	Hematuria 157	24.80% (219/883)
		Urinary irritation 38
		Urine retention 24

ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase.